Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

The open-label, nonrandomized, multiple-expansion cohort phase 1/2 trial evaluated the safety and efficacy of Krazati/Erbitux in patients with unresectable or metastatic KRAS G12C–mutated CRC.

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese ... Mirati’s MRTX1133 is in phase 1/1b testing, with results as a monotherapy due in ...